FACULTY
Kenneth H. Shain, MD, PhD
Associate Member
Department of Malignant Hematology,
Chemical Biology and Molecular Medicine Program
Co-Director
Pentecost Myeloma Research Center
Moffitt Cancer Center
Tampa, FL
PROGRAM OVERVIEW
This Virtual Preceptorship invites learners to explore the mechanisms of bispecific antibodies in the management of relapsed/refractory multiple myeloma. Novel bispecific antibodies simultaneously target CD3 on immune T cells and a target on malignant B cells, such as BCMA. By guiding T cells to malignant myeloma cells, bispecific antibodies enable the precise immune attack of malignant cells. In the process of immune attack, bispecific antibodies may trigger adverse events that require careful monitoring and multidisciplinary management. In this virtual reality program, clinicians will gain perspectives on both mechanisms and safe use of bispecific antibodies in patients with relapsed/refractory multiple myeloma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of oncologists, hematologists, hematology pharmacists, nurse practitioners, and physician assistants to ensure confidence in the management of relapsed/refractory multiple myeloma.
LEARNING OBJECTIVES
- Summarize the need for novel mechanisms to address unmet needs in the management of multiple myeloma
- Interpret mechanistic data with BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma
- Evaluate current data concerning BCMA-directed bispecific antibodies for the management of multiple myeloma
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty | Relationship | Manufacturer |
| Kenneth H. Shain, MD, PhD | Advisory Board | AbbVie, Amgen, Bristol Myers Squibb, GlaxoSmithKline and Janssen Received Honoraria Adaptive Biotechnologies Corporation, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, and Sanofi Genzyme Research Funding AbbVie and Karyopharm Therapeutics |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Michael Page, PharmD, RPh, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: January 24, 2024
EXPIRATION DATE: January 24, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
